Biejiajian Pill Promotes the Infiltration of CD8+ T Cells in Hepatocellular Carcinoma by Regulating the Expression of CCL5

Xuemei Yang, Jialing Sun, Bin Wen, Yu Wang, Mingjia Zhang, Weicong Chen, Wenting Zhao, Chunyu He, Xiaodan Zhong, Yang Liu, Tong Li, Haitao Sun, Songqi HeFrontiers in Pharmacology 2021 · DOI

TL;DR

This study reveals that Biejiajian Pill (BJJP), a traditional Chinese medicine, enhances the anti-tumor immune response in hepatocellular carcinoma (HCC) by increasing the infiltration of CD8+ T cells. This effect is mediated by BJJP's ability to upregulate the expression of the chemokine CCL5, which acts as a beacon to attract these crucial immune cells to the tumor site.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) remains a significant global health challenge, with current treatments having limitations. While tumor-infiltrating CD8+ T cells are known to be associated with better prognoses in many cancers, including HCC, the specific mechanisms by which traditional Chinese medicines like Biejiajian Pill (BJJP) might leverage this anti-tumor immunity have not been fully elucidated. Previous research indicated BJJP's direct cytotoxic effects on HCC cells, but this study aimed to explore its potential to modulate the tumor microenvironment and bolster the immune system's attack against cancer.

Methods

The researchers employed a multi-pronged approach to investigate BJJP's effects:

  • In vivo studies: They used H22-bearing mice (both immunocompetent BALB/c and immunodeficient BALB/c-nu/nu strains) to assess tumor growth, weight, and volume following BJJP treatment. TUNEL staining was used to evaluate apoptosis in tumor tissues.
  • Immune cell infiltration analysis: Immunofluorescence and fluorescence-activated cell sorting (FACS) were used to quantify CD8+ T cell infiltration into tumors.
  • Chemokine expression analysis: Real-time PCR and Western blotting were used to measure the mRNA and protein levels of various chemokines, with a particular focus on CCL5. ELISA was used to detect CCL5 levels in serum.
  • In vitro studies: Human HCC cell lines (HepG2 and SMMC-7721) were treated with BJJP to assess its effects on CCL5 expression.
  • Gene knockdown experiments: shRNA technology was used to specifically reduce CCL5 expression in H22 cells to understand its role in BJJP's anti-tumor effects.
  • Cell migration assays: Transwell assays were used to evaluate the migration of CD8+ T cells towards tumor cells in the presence and absence of BJJP, and with CCL5 knockdown.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from cell lines and animal models.

Key Insights and Ideas

  • BJJP as an immune modulator: Beyond direct cell killing, BJJP actively enhances the body's own defense mechanisms against HCC.
  • CCL5 as the key mediator: The study pinpoints CCL5 as a critical link between BJJP treatment and enhanced CD8+ T cell infiltration. This chemokine acts as a crucial signaling molecule.
  • Synergistic effects: BJJP's ability to promote CD8+ T cell infiltration appears to be dose-dependent, suggesting a nuanced therapeutic approach.
  • Translational relevance: The findings in mouse models were corroborated in human HCC cell lines, increasing the potential clinical applicability of BJJP.

Key Results

  • BJJP treatment significantly reduced tumor weight and volume in H22-bearing mice, with a more pronounced effect in immunocompetent mice, suggesting an immune-mediated component.
  • BJJP treatment led to a significant increase in the infiltration of CD8+ T cells into HCC tumors in vivo.
  • Among several chemokines assessed, CCL5 showed the most significant upregulation in tumors treated with BJJP, both at the mRNA and protein levels.
  • Knocking down CCL5 in H22 cells significantly impaired CD8+ T cell infiltration in vivo, demonstrating CCL5's essential role in BJJP's mechanism.
  • BJJP treatment also increased CCL5 mRNA and protein expression in human HCC cell lines (HepG2 and SMMC-7721).
  • BJJP treatment enhanced the migration of CD8+ T cells towards tumor cells in vitro.

Limitations and Future Work

  • Limited clinical data: While the study shows promising results in preclinical models and human cell lines, direct clinical trials are needed to confirm BJJP's efficacy and safety in human HCC patients.
  • Mechanism of CCL5 regulation: The study demonstrates that BJJP upregulates CCL5, but the precise molecular pathways by which BJJP achieves this regulation are not fully detailed. Further investigation into these pathways could reveal new therapeutic targets.
  • Comprehensive immune profiling: While CD8+ T cells were the focus, a broader analysis of other immune cell populations and their interactions within the tumor microenvironment could provide a more complete picture of BJJP's immunomodulatory effects.
  • Component analysis: BJJP is a complex herbal formula. Identifying the specific active compounds responsible for CCL5 upregulation and CD8+ T cell infiltration could lead to the development of more targeted and potent therapies.

Summary updated

Abstract

Tumor-infiltrating CD8<sup>+</sup>T lymphocytes are mostly associated with a favorable prognosis in numerous cancers, including hepatocellular carcinoma (HCC). Biejiajian Pill (BJJP) is a common type of traditional Chinese medicine that is widely used in the treatment of HCC in China. Previous studies showed that BJJP suppressed the growth of HCC cells both <i>in vivo</i> and <i>in vitro</i>, by exerting direct cytotoxic effects on tumor cells. The present study demonstrated that in addition to direct cytotoxicity, BJJP inhibits the growth of tumor cells by promoting the infiltration of CD8<sup>+</sup>T cells into the tumor in H<sub>22</sub>-bearing mice. Mechanistically, chemokine ligand 5 (CCL5) was identified as one of the most highly expressed chemokines by tumor cells <i>in vivo</i> after treatment with BJJP. Additionally, CCL5 was knocked down in H<sub>22</sub> cells and the results showed that knockdown of the gene significantly impaired the infiltration of CD8<sup>+</sup>T cells <i>in vivo</i>. Furthermore, the effects of BJJP on human HCC cell lines were assessed <i>in vitro</i>. Similarly, cells treated with BJJP had higher expression of CCL5 mRNA, which was consistent with increased levels of CCL5 protein in human tumor cells. These findings provide new insights into the anticancer effects of BJJP, which regulated the expression of CCL5 and the infiltration of CD8<sup>+</sup>T cells. The results, therefore, suggest that BJJP has great potential application in clinical practice.
BibTeX
@inproceedings{yang2021biejiajian,
  author = {Xuemei Yang and Jialing Sun and Bin Wen and Yu Wang and Mingjia Zhang and Weicong Chen and Wenting Zhao and Chunyu He and Xiaodan Zhong and Yang Liu and Tong Li and Haitao Sun and Songqi He},
  title = {{Biejiajian Pill Promotes the Infiltration of CD8+ T Cells in Hepatocellular Carcinoma by Regulating the Expression of CCL5}},
  booktitle = {Frontiers in Pharmacology},
  year = {2021},
  doi = {10.3389/fphar.2021.771046},
}
Figure